NCT00420680 is a Phase 3 clinical trial of Sugammadex in Anesthesia, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT00420680?

NCT00420680 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00420680?

Interventions in NCT00420680: Sugammadex, Sugammadex, Placebo.

What condition does NCT00420680 study?

NCT00420680 studies Anesthesia.

Is NCT00420680 still recruiting?

NCT00420680 is currently completed. Last updated 22 August 2017.

Last reviewed 2017-08-22 · How we verify

NCT00420680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

Completed Phase 3 Last updated 22 August 2017

What this trial tests

Phase 3 trial testing Sugammadex in Anesthesia in 120 participants. Completed in 1 August 2006.

Timeline

7 November 2005

Primary endpoint
1 August 2006

1 August 2006

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	7 November 2005
Primary completion	1 August 2006
Estimated completion	1 August 2006

Drugs / interventions tested

Sugammadex — full drug profile →
Sugammadex — full drug profile →
Placebo

Conditions studied

Anesthesia — all drugs for Anesthesia →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety of 2.0 mg/kg and 4.0 mg/kg sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium in cardiac patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sugammadex

Trials testing the same drug.

NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
NCT07271875 — Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery · Phase 3 · not yet recruiting
NCT07309393 — Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function · NA · recruiting
NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
NCT06575036 — Sugammadex Dose Finding Under Two Years Old · Phase 2 · not yet recruiting

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
NCT07443254 — Prospective IR-led Sedation Feasibility · Phase 1, PHASE2 · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00420680 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 22 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00420680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing